西马鲁肽对糖尿病相关足溃疡患者伤口愈合的影响:TriNetX数据库研究

IF 3
Diabetes & vascular disease research Pub Date : 2025-03-01 Epub Date: 2025-03-13 DOI:10.1177/14791641251322909
Joshua E Lewis, Diana K Omenge, Amani R Patterson, Ogechukwu Anwaegbu, Nangah N Tabukum, Jimmie E Lewis, Wei-Chen Lee
{"title":"西马鲁肽对糖尿病相关足溃疡患者伤口愈合的影响:TriNetX数据库研究","authors":"Joshua E Lewis, Diana K Omenge, Amani R Patterson, Ogechukwu Anwaegbu, Nangah N Tabukum, Jimmie E Lewis, Wei-Chen Lee","doi":"10.1177/14791641251322909","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionDiabetes related foot ulcers (DFUs) are common complications of type 2 diabetes mellitus (T2DM), affecting 15-25% of individuals living with diabetes and significantly contributing to healthcare costs ($9-13 billion annually in the U.S.). Without effective management, these wounds often lead to severe outcomes like amputations. This study aims to examine the association of semaglutide on DFU management.MethodsThis retrospective cohort study utilized TriNetX US Research Network data to assess the impact of semaglutide, a GLP-1 receptor agonist, on DFU outcomes between 2013 and 2023. The study compared outcomes between semaglutide users with DFU (Cohort A, <i>N</i> = 6329) and non-users with DFU (Cohort B, <i>N</i> = 118,821) across 64 healthcare organizations. We matched participants by age, gender, race, and ethnicity; however, we excluded patients with certain co-morbidities. Statistical analysis, such as chi-square analysis and risk ratio, using TriNetX software evaluated different complication outcomes.ResultsSemaglutide users with DFU demonstrated lower relative risks for complications compared to non-users. Within 1 year, semaglutide users were associated with lower relative risks for wound healing complications (0.19% vs 0.38%), chronic non-healing wounds (0.75% vs 1.23%), chronic pain (4.44% vs 8.06%), wound care (2.42% vs 4.86%), wound dehiscence (0.26% vs 0.56%), and amputation (2.34% vs 5.21%) (<i>p</i> < .05). Similar trends persisted over 5 years. While these findings highlight potential benefits of semaglutide with patients with DFU, causation cannot be inferred due to the study's observational design.ConclusionSemaglutide use was associated with favorable outcomes in patients with diabetes-related foot ulcers, including reductions in wound-related complications. While these findings suggest potential benefits of semaglutide as an adjunct in DFU management, further research is needed to confirm these associations and to better understand the mechanisms involved.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"22 2","pages":"14791641251322909"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907515/pdf/","citationCount":"0","resultStr":"{\"title\":\"The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study.\",\"authors\":\"Joshua E Lewis, Diana K Omenge, Amani R Patterson, Ogechukwu Anwaegbu, Nangah N Tabukum, Jimmie E Lewis, Wei-Chen Lee\",\"doi\":\"10.1177/14791641251322909\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>IntroductionDiabetes related foot ulcers (DFUs) are common complications of type 2 diabetes mellitus (T2DM), affecting 15-25% of individuals living with diabetes and significantly contributing to healthcare costs ($9-13 billion annually in the U.S.). Without effective management, these wounds often lead to severe outcomes like amputations. This study aims to examine the association of semaglutide on DFU management.MethodsThis retrospective cohort study utilized TriNetX US Research Network data to assess the impact of semaglutide, a GLP-1 receptor agonist, on DFU outcomes between 2013 and 2023. The study compared outcomes between semaglutide users with DFU (Cohort A, <i>N</i> = 6329) and non-users with DFU (Cohort B, <i>N</i> = 118,821) across 64 healthcare organizations. We matched participants by age, gender, race, and ethnicity; however, we excluded patients with certain co-morbidities. Statistical analysis, such as chi-square analysis and risk ratio, using TriNetX software evaluated different complication outcomes.ResultsSemaglutide users with DFU demonstrated lower relative risks for complications compared to non-users. Within 1 year, semaglutide users were associated with lower relative risks for wound healing complications (0.19% vs 0.38%), chronic non-healing wounds (0.75% vs 1.23%), chronic pain (4.44% vs 8.06%), wound care (2.42% vs 4.86%), wound dehiscence (0.26% vs 0.56%), and amputation (2.34% vs 5.21%) (<i>p</i> < .05). Similar trends persisted over 5 years. While these findings highlight potential benefits of semaglutide with patients with DFU, causation cannot be inferred due to the study's observational design.ConclusionSemaglutide use was associated with favorable outcomes in patients with diabetes-related foot ulcers, including reductions in wound-related complications. While these findings suggest potential benefits of semaglutide as an adjunct in DFU management, further research is needed to confirm these associations and to better understand the mechanisms involved.</p>\",\"PeriodicalId\":93978,\"journal\":{\"name\":\"Diabetes & vascular disease research\",\"volume\":\"22 2\",\"pages\":\"14791641251322909\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907515/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & vascular disease research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/14791641251322909\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & vascular disease research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/14791641251322909","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

糖尿病相关足部溃疡(DFUs)是2型糖尿病(T2DM)的常见并发症,影响了15-25%的糖尿病患者,并显著增加了医疗费用(美国每年的医疗费用为90 - 130亿美元)。如果没有有效的治疗,这些伤口往往会导致严重的后果,如截肢。本研究旨在探讨西马鲁肽与DFU治疗的关系。方法:本回顾性队列研究利用TriNetX美国研究网络数据,评估2013年至2023年期间,GLP-1受体激动剂semaglutide对DFU结局的影响。该研究比较了64个医疗机构中使用西马鲁肽的DFU患者(队列A, N = 6329)和不使用DFU的患者(队列B, N = 118,821)的结果。我们按年龄、性别、种族和民族对参与者进行匹配;然而,我们排除了有某些合并症的患者。采用TriNetX软件对不同并发症结局进行卡方分析、风险比等统计分析。结果与非使用者相比,使用西马鲁肽的DFU患者出现并发症的相对风险较低。1年内,使用西马鲁肽的患者伤口愈合并发症(0.19% vs 0.38%)、慢性不愈合伤口(0.75% vs 1.23%)、慢性疼痛(4.44% vs 8.06%)、伤口护理(2.42% vs 4.86%)、伤口裂开(0.26% vs 0.56%)和截肢(2.34% vs 5.21%)的相对风险较低(p < 0.05)。类似的趋势持续了5年。虽然这些发现强调了西马鲁肽对DFU患者的潜在益处,但由于研究的观察性设计,无法推断因果关系。结论:使用semaglutide与糖尿病相关足部溃疡患者的良好预后相关,包括伤口相关并发症的减少。虽然这些发现表明西马鲁肽作为DFU治疗辅助药物的潜在益处,但需要进一步的研究来证实这些关联并更好地了解所涉及的机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study.

IntroductionDiabetes related foot ulcers (DFUs) are common complications of type 2 diabetes mellitus (T2DM), affecting 15-25% of individuals living with diabetes and significantly contributing to healthcare costs ($9-13 billion annually in the U.S.). Without effective management, these wounds often lead to severe outcomes like amputations. This study aims to examine the association of semaglutide on DFU management.MethodsThis retrospective cohort study utilized TriNetX US Research Network data to assess the impact of semaglutide, a GLP-1 receptor agonist, on DFU outcomes between 2013 and 2023. The study compared outcomes between semaglutide users with DFU (Cohort A, N = 6329) and non-users with DFU (Cohort B, N = 118,821) across 64 healthcare organizations. We matched participants by age, gender, race, and ethnicity; however, we excluded patients with certain co-morbidities. Statistical analysis, such as chi-square analysis and risk ratio, using TriNetX software evaluated different complication outcomes.ResultsSemaglutide users with DFU demonstrated lower relative risks for complications compared to non-users. Within 1 year, semaglutide users were associated with lower relative risks for wound healing complications (0.19% vs 0.38%), chronic non-healing wounds (0.75% vs 1.23%), chronic pain (4.44% vs 8.06%), wound care (2.42% vs 4.86%), wound dehiscence (0.26% vs 0.56%), and amputation (2.34% vs 5.21%) (p < .05). Similar trends persisted over 5 years. While these findings highlight potential benefits of semaglutide with patients with DFU, causation cannot be inferred due to the study's observational design.ConclusionSemaglutide use was associated with favorable outcomes in patients with diabetes-related foot ulcers, including reductions in wound-related complications. While these findings suggest potential benefits of semaglutide as an adjunct in DFU management, further research is needed to confirm these associations and to better understand the mechanisms involved.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信